首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1238754篇
  免费   76644篇
  国内免费   1780篇
耳鼻咽喉   17380篇
儿科学   40838篇
妇产科学   33514篇
基础医学   175158篇
口腔科学   34503篇
临床医学   107697篇
内科学   232708篇
皮肤病学   28253篇
神经病学   91660篇
特种医学   52039篇
外国民族医学   287篇
外科学   187912篇
综合类   22668篇
现状与发展   1篇
一般理论   265篇
预防医学   88882篇
眼科学   28186篇
药学   97569篇
  9篇
中国医学   2931篇
肿瘤学   74718篇
  2018年   14610篇
  2017年   12545篇
  2016年   13066篇
  2015年   15715篇
  2014年   19197篇
  2013年   25362篇
  2012年   39416篇
  2011年   36506篇
  2010年   20932篇
  2009年   21283篇
  2008年   31879篇
  2007年   34660篇
  2006年   35499篇
  2005年   41481篇
  2004年   41597篇
  2003年   36227篇
  2002年   30671篇
  2001年   63416篇
  2000年   62903篇
  1999年   55328篇
  1998年   12915篇
  1997年   11261篇
  1996年   11351篇
  1995年   10625篇
  1994年   9649篇
  1993年   9110篇
  1992年   43046篇
  1991年   41733篇
  1990年   41406篇
  1989年   39778篇
  1988年   35946篇
  1987年   34826篇
  1986年   32862篇
  1985年   30591篇
  1984年   22044篇
  1983年   18447篇
  1982年   9611篇
  1979年   20095篇
  1978年   13297篇
  1977年   11677篇
  1976年   10105篇
  1975年   12054篇
  1974年   14221篇
  1973年   13520篇
  1972年   13037篇
  1971年   12419篇
  1970年   11447篇
  1969年   11041篇
  1968年   9842篇
  1967年   8956篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.
5.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
6.
7.
8.
9.
10.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号